A method of treating gamma oncogenic herpesviruses, in vivo, through use of Delta-9 Tetrahydrocannabinol (THC). THC inhibits KSHV and EBV reactivation as well as inhibiting lytic replication of MHV 68 and HVS in vitro. Specifically, THC inhibits immediate early gene ORF 50 promoter activity